Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Selpercatinib Formulations
NCT05089019Phase 1Completed
- Sponsor
- Loxo Oncology
- Start
- Oct 2021
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), thyroid cancer and 1 more (2 arms), sponsored by Loxo Oncology. Primary endpoints: Maximum Concentration at Day 15, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity at Day 15 and 1 more. Started Oct 2021; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancersolid tumor
Beyond the preview
Go deeper on NCT05089019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089019.